Compare Wegovy 1.7mg vs Mounjaro Treatment Options
Prescription Weight Loss: 1.7mg Wegovy to Mounjaro Clinical Differences
When comparing 1.7mg Wegovy to Mounjaro as prescription weight loss treatments, understanding their distinct mechanisms becomes essential for informed treatment decisions. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones to reduce appetite and promote satiety after smaller meals. Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors, offering a dual incretin approach to weight management.
Both prescription-only medicines require clinical assessment and ongoing prescriber supervision throughout treatment. The 1.7mg Wegovy dose represents weeks 13-16 of the established escalation protocol, positioning patients near maintenance dosing. Mounjaro follows its own titration schedule, with different dose intervals and maintenance targets. Your prescriber can determine which treatment pathway aligns best with your individual weight management goals and clinical profile.
1.7mg Wegovy to Mounjaro Pricing and Value Comparison
Wegovy 1.7mg costs £139.99 per pen through EverydayMeds, representing weeks 13-16 of treatment when results typically accelerate. For patients planning their transition to maintenance dosing, our Elevate Duo bundle (1.7mg + 2.4mg) provides seamless progression for £369.99. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to maintain optimal pricing across their treatment journey.
Mounjaro pricing follows similar prescription medication principles, with costs varying by dose strength and treatment stage. Both treatments require genuine clinical assessment through our 3-minute online process, followed by prescriber review within 3 working days (or 24 hours with express service). Bundle options provide treatment continuity without frequent reordering, particularly valuable when comparing 1.7mg Wegovy to Mounjaro for long-term weight management planning.
Clinical Evidence: 1.7mg Wegovy to Mounjaro Trial Outcomes
In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The 1.7mg dose represents a critical escalation point where many patients experience accelerated results before reaching 2.4mg maintenance dosing. STEP trial participants maintained significant weight loss throughout the 2-year follow-up period when treatment continued.
Mounjaro's clinical evidence demonstrates its own efficacy profile through separate trial programmes with different patient populations and study designs. Both treatments show cardiovascular benefits beyond weight loss, with Wegovy's SELECT trial demonstrating 20% reduction in major cardiovascular events. When comparing 1.7mg Wegovy to Mounjaro, both represent evidence-based approaches to prescription weight management under appropriate clinical supervision.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking incretin hormones that naturally regulate appetite and blood sugar response after eating. The medication works on brain appetite centres to reduce food cravings whilst promoting feelings of fullness after smaller meal portions. This dual action supports sustainable eating pattern changes alongside prescribed dietary modifications. Weekly injection timing maintains consistent therapeutic levels throughout each dosing interval. The 1.7mg strength provides substantial receptor activation whilst patients assess tolerance before advancing to 2.4mg maintenance dosing.
Ordering Process: 1.7mg Wegovy to Mounjaro Assessment
Starting your comparison of 1.7mg Wegovy to Mounjaro begins with our comprehensive 3-minute clinical assessment, covering medical history, current medications, and weight management goals. Our prescribers review each application within 3 working days (24-hour express service available) to determine treatment suitability and recommend optimal medication choice. Once approved, medications ship via next-day cold-chain delivery to maintain temperature-controlled integrity throughout transit. Our GPhC-registered pharmacy (#9012878) ensures genuine UK-licensed supply with full pharmaceutical oversight. Treatment monitoring continues throughout your weight management journey with ongoing prescriber support.
Storage and Practical Considerations: Wegovy vs Mounjaro
Wegovy offers significant practical advantages with 6 weeks room temperature storage once removed from refrigeration, compared to Mounjaro's 21-day limit below 30°C. Both medications require initial refrigerated storage at 2-8°C before first use, making travel and lifestyle flexibility important considerations. The FlexTouch pen delivery system provides accurate dosing with simple injection technique suitable for self-administration. Dose escalation protocols differ between treatments, with Wegovy following established 4-week intervals through 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg progression. Neither medication can skip doses safely, making adherence to prescribed escalation schedules essential for optimal outcomes.
Treatment Pathway: Transitioning from 1.7mg Wegovy to Mounjaro Considerations
Patients considering switching from 1.7mg Wegovy to Mounjaro require careful clinical evaluation and potential washout periods between treatments. The 1.7mg Wegovy dose represents advanced treatment progress, typically achieved after 16 weeks of gradual escalation and clinical monitoring. Transitioning between GLP-1 treatments involves prescriber assessment of current response, side effect tolerance, and individual treatment goals.
Some patients may benefit from Mounjaro's dual incretin approach if Wegovy response plateaus, whilst others achieve optimal outcomes continuing Wegovy progression to 2.4mg maintenance. Both medications require prescription-only medicine status with ongoing clinical oversight throughout treatment duration. Your prescriber can evaluate timing, safety considerations, and optimal transition protocols if treatment changes become clinically appropriate.
Complete Your 1.7mg Wegovy to Mounjaro Assessment Today
Both Wegovy and Mounjaro are available from EverydayMeds with expert clinical assessment to determine which treatment best supports your weight management goals. Our comprehensive evaluation process ensures appropriate medication selection based on individual clinical factors, lifestyle considerations, and treatment preferences. New customers use code FIRST40 whilst returning customers apply DOSE25 for optimal pricing on both treatment options. Complete your assessment at https://everydaymeds.co.uk/products/wegovy-1-7mg or explore our complete range of weight management treatments. Your prescriber can help determine whether 1.7mg Wegovy to Mounjaro represents the right treatment pathway for sustainable weight management success.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
